为了实现多发性硬化症的初级预防
Ruth Dobson1,2, Karim L Kreft3,4, Benjamin M Jacobs5,6
1Centre for Preventive Neurology, Wolfson Institute of Population Health, Queen Mary University London, London, UK. Ruth.dobson@qmul.ac.uk.
Nature reviews. Neurology
|November 27, 2025
概括
在症状出现之前预防多发性硬化症 (MS) 是一个关键目标. 需要新的策略和试验设计,以克服开发有效的MS预防干预措施的挑战.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 临床试验设计 临床试验设计
背景情况:
- 多发性硬化症 (MS) 是年轻人残疾的主要原因,尽管有先进的治疗方法,但仍然是一个无法治愈的神经系统疾病.
- 在脱髓化发作之前预防MS是一种雄心勃勃但可行的目标,但目前的预防策略缺乏强有力的有效性证据.
- 在MS预防研究中的挑战包括风险因素的影响小,干预窗口有限,疾病的发病率相对较低.
研究的目的:
- 讨论与开发和评估多发性硬化症预防性干预相关的重大挑战.
- 为MS预防研究提出新的策略和解决方案,从其他疾病领域的进展中汲取灵感.
- 突出创新的试验设计,风险分层和结果定义在推进MS预防研究中的重要性.
主要方法:
- 这篇观点回顾了现有的文献,并讨论了MS预防研究中的概念和实际困难.
- 它检查了相关领域的进展,例如对放射性隔离综合征的研究,以告知新的方法.
- 作者提出了风险分层的务实策略,统计权考虑,以及未来预防试验的结果定义.
主要成果:
- 传统的随机对照试验设计在MS预防的背景下面临重大障碍.
- 新的方法,包括对放射性隔离综合征的研究,正在为MS预防研究提供动力.
- 对风险分层的务实方法以及对统计能力和结果定义的仔细考虑对于成功的干预研究至关重要.
结论:
- 开发和测试多发性硬化症的预防性干预措施需要仔细规划风险分层,沟通,干预和结果措施.
- 尽管存在复杂性,但目前的科学理解支持迫切需要启动MS预测和预防研究.
- 创新的试验设计和战略规划对于克服建立有效的MS预防策略所固有的困难至关重要.
相关概念视频
01:26Levels of Health Promotion and Illness Prevention
14.1K
Health promotion allows a person to control the determinants of health, resulting in an improved health status. It enhances the quality of life and reduces premature deaths. Health promotion and illness prevention programs help people make beneficial choices to reduce the risk of disease and disabilities. There are three health promotion and illness prevention levels: primary, secondary, and tertiary prevention.
In primary prevention, actions taken before disease onset prevent the disease from...
In primary prevention, actions taken before disease onset prevent the disease from...
14.1K
01:30Preventive Healthcare Services
1.8K
Preventive healthcare services keep people healthy via frequent check-ups, screening, and counseling. They primarily aid in disease prevention rather than treating an acute or chronic illness. Preventive treatment also keeps individuals productive and energetic, allowing them to work well into their retirement years. Examples of preventive care services include:
1.8K
01:20Myasthenia Gravis: Overview and Treatment
2.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.7K
01:26Atherosclerosis III: Management
296
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
296